Medical Application of Bioactive Preparations that Contain Growth Factors of Human Platelets

The use of biopreparations based on platelet-rich plasma (PRP) is one of the promising areas in
regenerative medicine, which has been actively developing in the latest decade. In addition, when
obtaining cell products for therapy and tissue engineering, bioactive substances that regulate cell
proliferation and differentiation, which contain the main growth factors also produced by platelets,
are used.
Purpose. To assess the effectiveness of bioactive preparations that contain platelet growth factors in
their usage for treatment of long-term non-healing wounds of the skin of the extremities in patients
with diabetes mellitus and chronic ischemia in the lower limbs of non-diabetic genesis, as well as a
bioactive additive in the production of biomedical cell products based on mesenchymal stem cells.
Materials and methods. We studied the clinical effectiveness of PRP in the complex therapy of
patients with chronic ischemia in the lower limbs of atherosclerotic genesis (n=16) and long-term
non-healing wounds of the skin of the extremities in patients with diabetes (n=14). The efficiency of
using the lysed platelet concentrate to obtain a biomedical cell product of mesenchymal cells was
studied on 46 samples of cells obtained from the bone marrow of healthy donors (n=16), patients
with multiple sclerosis (n=16), as well as from the adipose tissue of deceased donors (n=14).
Results. The use of PRP in patients with chronic ischemia in the lower limbs of atherosclerotic
genesis provided the increase of painless walking distance from 152 [100; 197] to 189 [151; 202]
meters within 1 month of therapy with further positive dynamics within 6 months. In some patients,
6 months later, there was the regression of clinical symptoms with the change of the chronic arterial
insufficiency stage from IIb to IIa. In patients with long-term non-healing ulcers of the skin of the
extremities on the background of diabetes, complete wound healing occurred within 4–6 weeks
after the initial use of PRP, followed by maintaining the integrity of the skin for 12 months. The
addition of 5% lysed platelet concentrate to the culture medium provided the 1.6–2.4-fold reduction
of the cultivation time of mesenchymal cells if compared with the use of 10% FBS.
Conclusion. Bioactive drugs based on human platelets stimulate regenerative processes in damaged
tissues, providing the increase of the effectiveness of complex therapy for chronic ischemia in the
lower limbs of various origins; they are also highly effective and safe when used in the technological
process of producing biomedical cell products.